ClinicalTrials.gg
CompletedNCT04633057Updated Apr 15, 2024

A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency

A Phase 3 interventional study of TJ101 and NordiFlex in Pediatric Growth Hormone Deficiency, sponsored by TJ Biopharma Co., Ltd.. Completed at 30 sites in China. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by TJ Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Study summary

A Phase III, Randomized, open-label, positive-drug parallel control, Study to Evaluate the Efficacy and Safety of TJ101 in Child subject with growth hormone deficieney.

02

Conditions studied

  • Pediatric Growth Hormone Deficiency
03

In context

Lead sponsor

TJ Biopharma Co., Ltd. is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Boys: 3 years ≤ boy's age ≤ 10 years;Girls: 3 years ≤ girl's age ≤ 9 years
  2. Pre-pubertal children(Tanner stage I)
  3. GHD confirmed by 2 different GH provocation tests with peak GH concentration below 10 ng/mL in screening or one month
  4. Height (HT) of at least 2.0 standard deviations (SD) below the mean height for chronological age (CA) and gender according to Table of standard deviation unit values of age and height of Chinese children aged 3-12 years , (HT SDS ≤ -2.0)
  5. Height velocity≤5.0cm/years (Including height records before at least three months);
  6. IGF-1 SDS≤-1.0
  7. Bone age (BA) is no more than two chronological age
  8. (BMI) must be within ±2 SD of mean BMI for the chronological age and sex according to Table of standard deviation unit values of Age and BMI of Chinese children aged 3-12 years
  9. Without prior exposure to any rhGH therapy
  10. For children with growth hormone deficiency that is one of its multiple pituitary hormone deficiencies, alternative therapies targeting the hypothalamus-pituitary-target gland axis must be used for at least 3 months before screening
  11. Written of the parent or legal guardian of the subject and assent of the subject (if the subject can read)

Exclusion criteria

Exclusion Criteria:

  1. beyond physiological dosage of therapy
  2. Evidence of closed epiphyses
  3. Any other chronic condition that can cause short stature and cannot be treated with hormone replacement therapy(Including but not limited Chronic kidney disease, malnutrition, absorption disorders, uncontrolled hypothyroidism, celiac disease, rickets and social-psychological dwarfism)
  4. Abnormal liver and renal function (>1.5 times the and Cr exceeding the upper limit of normal range)
  5. Presence of anti-hGH antibodies at screening
  6. Concomitant administration of other treatments that may have an effect on growth such as anabolic steroids, with the exception of ADHD(attention deficit hyperactivity disorder) drug hormone replacement therapies [thyroxine, hydrocortisone, desmopressin (DDAVP)]
  7. Mutations in growth hormone receptors are suspected, or any syndrome that causes insensitivity to growth hormone
  8. At screening, ophthalmologic examination (including fundus microscopy) indicated increased intracranial pressure and/or retinopathy.
  9. At screening, previous or existing intracranial tumor growth was confirmed by cranial magnetic resonance imaging (MRI) scan (using contrast agent) (MRI results up to 1 year prior to screening were acceptable)
  10. Diseases such as severe cardiopulmonary, blood system, malignant tumor or potential tumor (family history), or systemic infection, low immune function and mental diseases
  11. Significant spinal abnormalities, including scoliosis (Cobb Angle \& GT;60 ˚), kyphosis and spina bifida.
  12. Subjects diagnosed with type 2 or type 1 diabetes who were considered to have received no standard treatment, did not follow their prescribed treatment, or exhibited poor metabolic control, or had fasting glucose > 5.6 mmol/L twice in a row
  13. Chromosomal abnormalities and medical syndromes (Turner's syndrome, Laron syndrome, Noonan syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, SHOX mutations/deletions and skeletal dysplasias), with the exception of septo-optic dysplasia
  14. Children with low birth weight (birth weight and/or body length are 2 SD below average according to the standard of the general Chinese population of the same gestational age and sex)
  15. The subject and/or the parent/legal guardian are likely to be non-compliant in respect to study conduct
  16. Subject who has received an product or has participated in a clinical study within 30 days before screening or during the clinical trials.
  17. Known or suspected to be positive, serologically positive for syphilis, or other chronic infectious diseases, such as AIDS, tuberculosis, hepatitis, etc
  18. The history of drug, drug or alcohol abuse
  19. Other conditions not considered suitable for inclusion by the researchers
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    TJ101

    TJ101 1.2 mg/kg once a week for 52weeks

    Drug: TJ101

  • Active comparator
    NordiFlex

    NordiFlex Injection 0.034 mg/kg once a day for 52 weeks

    Drug: NordiFlex

Interventions

  • DrugAnti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101Studies of Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.

  • DrugNordiFlex

    TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.

06

What researchers measure

Primary outcomes

  1. The Annualized Height velocity at 52 week

    The Annualized Height velocity at 52 week

    Time frame: 52weeks after first dose

Secondary outcomes

  1. change in Annualized Height velocity at 26 week (compared to Baseline value)

    Time frame: 26weeks after first dose

  2. change in Annualized Height velocity at 52 week (compared to Baseline value)

    Time frame: 52weeks after first dose

07

Study locations

30 sites
  • Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Beijing Children's Hospital,Capital Medical University
    Beijing, Beijing, China
  • Children's Hospital, Capital Institute of Paediatrics
    Beijing, Beijing, China
  • Chongqing Three Gorges Central Hospital
    Wanzhou, Chongqing, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • The Third Affiliated Hospital of Sun Yet-sen University
    Guangzhou, Guangdong, China
  • Liuzhou Maternity and Children Healthcare Hospital
    Liuzhou, Guangxi, China
  • Hainan Third People's Hospital
    Sanya, Hainan, China
  • Tangshan Women and Children's Hospital
    Tangshan, Hebei, China
  • Henan Children's Hospital
    Zhengzhou, Henan, China
  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Wuhan Children's Hospital
    Wuhan, Hubei, China
  • Hunan Children's Hospital
    Changsha, Hunan, China
  • The First Affiliated Hospital of Nanhua University
    Hengyang, Hunan, China
  • Children's Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
  • Jiangsu Provincial Maternal and Child Health Hospital
    Nanjing, Jiangsu, China
  • Children's Hospital affiliated to Soochow University
    Suzhou, Jiangsu, China
  • Jiangxi Provincial Children's Hospital
    Nanchang, Jiangxi, China
  • Pingxiang Maternity and Child Care Hospital
    Pingxiang, Jiangxi, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia, China
  • Affiliated Hospital of Jining Medical College
    Jining, Shandong, China
  • Linyi Women and Children's Hospital
    Linyi, Shandong, China
  • Shanghai Children's Medical Center
    Shanghai, Shanghai, China
  • Shanghai Jiaotong University School of Medicine Ruijin Hospital
    Shanghai, Shanghai, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan, China
  • West China Second Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Taizhou First People's Hospital
    Liuzhou, Zhejiang, China
  • Ningbo Women & Children's Hospital
    Ningbo, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jul 2023, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2020
First posted
Nov 18, 2020
StartActual
Jan 25, 2021
Primary completionActual
Jul 31, 2023
CompletionActual
Jul 31, 2023
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04633057
Lead sponsor
TJ Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Jan 25, 2021
Primary completion
Jul 31, 2023
Completion
Jul 31, 2023
Last update
Apr 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101

Start the discussion